Associations - DNA synthesis inhibitor

No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 1wk	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week capecitabine + mitomycin Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week (New A2) gemcitabine Sensitive : A2 NCCN - 1wk	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week gemcitabine Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 1wk	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week capecitabine + mitomycin Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week (New A2) capecitabine + mitomycin Sensitive : A2 NCCN - 1wk	capecitabine + mitomycin Sensitive: A2 - Guideline NCCN - 1 week capecitabine + mitomycin Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week (New A2) gemcitabine Sensitive : A2 NCCN - 1wk	gemcitabine Sensitive: A2 - Guideline NCCN - 1 week gemcitabine Sensitive : A2 NCCN - 1 week - (New A2)
LOX overexpression	Ovarian Cancer	LOX overexpression	Ovarian Cancer	cisplatin Sensitive: D – Preclinical ESGO 2023 - 2 weeks (New D) cisplatin Sensitive : D ESGO 2023 - 2wk	cisplatin Sensitive: D – Preclinical ESGO 2023 - 2 weeks cisplatin Sensitive : D ESGO 2023 - 2 weeks - (New D)
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1	nelarabine Sensitive: A1 - Approval nelarabine Sensitive : A1
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1	mercaptopurine Sensitive: A1 - Approval mercaptopurine Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + docetaxel Sensitive: A1 - Approval cisplatin + docetaxel Sensitive : A1	cisplatin + docetaxel Sensitive: A1 - Approval cisplatin + docetaxel Sensitive : A1
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	melphalan hepatic delivery system Sensitive: A1 - Approval melphalan hepatic delivery system Sensitive : A1	melphalan hepatic delivery system Sensitive: A1 - Approval melphalan hepatic delivery system Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2	cisplatin + docetaxel Sensitive: A2 - Guideline cisplatin + docetaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2

DNA synthesis inhibitor

DNA synthesis inhibitor

Associations(835)

Associations
(835)